What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to report on the Compensation Committee's approval of executive compensation arrangements, including performance units for the 2012-2014 period, and adjustments related to the upcoming CEO transition.

How is executive compensation tied to performance at Amgen?

Executive compensation, particularly through performance units and restricted stock units, is tied to Amgen's Total Shareholder Return (TSR) relative to a defined peer group. Dividend equivalents will also be granted on these awards starting from the 2012 grants.

What are the key changes for Kevin W. Sharer's compensation as he transitions out of the CEO role?

Kevin W. Sharer's compensation was adjusted to reflect his shortened service as CEO. The value of his performance units and RSUs was reduced, and certain pro-ration provisions that typically apply upon departure were waived for his grants. He will also continue to receive his base salary through the end of 2012 and have continued access to office support until 2017.

What compensation changes are being made for the new CEO, Robert A. Bradway?

Robert A. Bradway received a base salary increase to $1.4 million annually, effective May 21, 2012, and his target cash incentive award for 2012 was increased to 130% of his base salary.

AMGN 8-K: Leadership Changes

Summary

This 8-K filing from Amgen Inc. (AMGN) on March 19, 2012, primarily details adjustments to executive compensation and the terms of performance-based awards. Key information for investors includes the approval of performance units and their associated performance goals for the 2012-2014 period, which are structured similarly to prior awards but with an updated peer group. Notably, the filing addresses the upcoming CEO transition, outlining specific compensation arrangements for Kevin W. Sharer as he steps down and Robert A. Bradway's promotion to CEO. Investors should pay close attention to the details regarding the performance metrics, particularly the total shareholder return (TSR) comparison against a peer group, as this will directly impact potential payouts for senior executives. The amendments to the performance program to include dividend equivalents on restricted stock units and performance units are also a significant development. Furthermore, the compensation adjustments for the incoming CEO and other executive vice presidents indicate a strategic approach to incentivizing leadership during a period of transition.

Key Highlights

1Amgen's Compensation Committee approved performance units and goals for the 2012-2014 performance period under the 2009 Performance Award Program.
2The performance units are tied to Amgen's Total Shareholder Return (TSR) compared to an updated peer group, which now includes Allergan and Celgene.
3The payout percentage is calculated as 100% plus two times the percentage difference between Amgen's TSR and the peer group's average TSR, with a maximum payout of 150% of target units.
4Amendments were made to the Performance Program and RSU agreements to grant dividend equivalents on all RSU and performance unit grants, commencing with the 2012-2014 awards.
5Kevin W. Sharer's compensation package was adjusted to reflect his planned departure as CEO on May 23, 2012, including a reduced grant value for performance units and RSUs and the waiver of pro-ration provisions upon his departure.
6Robert A. Bradway's compensation was adjusted upon his promotion to CEO, including a base salary increase to $1.4 million and an increased target cash incentive award of 130% of base salary.
7Target cash incentive awards for Amgen's executive vice presidents were increased from 80% to 90% of base salary for 2012.

AMGEN INC 8-K Report, Executive Changes (Mar 20, 2012)

Summary

Key Highlights

Frequently Asked Questions